|
1
|
Clark PI and Slevin ML: The clinical
pharmacology of etoposide and teniposide. Clin Pharmacokinet.
12:223–252. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Jong RS, Mulder NH, Dijksterhuis D and
de Vries EG: Review of current clinical experience with prolonged
(oral) etoposide in cancer treatment. Anticancer Res. 15:2319–2330.
1995.PubMed/NCBI
|
|
3
|
van Maanen JM, de Vries J, Pappie D, van
den Akker E, Lafleur VM, Retel J, van der Greef J and Pinedo HM:
Cytochrome P-450-mediated O-demethylation: a route in the metabolic
activation of etoposide (VP-16–213). Cancer Res. 47:4658–4662.
1987.PubMed/NCBI
|
|
4
|
Relling MV, Nemec J, Schuetz EG, Schuetz
JD, Gonzalez FJ and Korzekwa KR: O-demethylation of
epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol
Pharmacol. 45:352–358. 1994.PubMed/NCBI
|
|
5
|
Kawashiro T, Yamashita K, Zhao XJ, Koyama
E, Tani M, Chiba K and Ishizaki T: A study on the metabolism of
etoposide and possible interactions with antitumor or supporting
agents by human liver microsomes. J Pharmacol Exp Ther.
286:1294–1300. 1998.PubMed/NCBI
|
|
6
|
Leu BL and Huang JD: Inhibition of
intestinal P-glycoprotein and effects on etoposide absorption.
Cancer Chemother Pharmacol. 35:432–436. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Makhey VD, Guo A, Norris DA, Hu P, Yan J
and Sinko PJ: Characterization of the regional intestinal kinetics
of drug efflux in rat and human intestine and in Caco-2 cells.
Pharm Res. 15:1160–1167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lagas JS, Fan L, Wagenaar E, Vlaming ML,
van Tellingen O, Beijnen JH and Schinkel AH: P-glycoprotein
(P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of
etoposide. Clin Cancer Res. 16:130–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lum BL, Kaubisch S, Yahanda AM, Adler KM,
Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP and Sikic BI:
Alteration of etoposide pharmacokinetics and pharmacodynamics by
cyclosporine in a phase I trial to modulate multidrug resistance. J
Clin Oncol. 10:1635–1642. 1992.PubMed/NCBI
|
|
10
|
Carcel-Trullols J, Torres-Molina F, Araico
A, Saadeddin A and Peris JE: Effect of cyclosporine A on the tissue
distribution and pharmacokinetics of etoposide. Cancer Chemother
Pharmacol. 54:153–160. 2004.PubMed/NCBI
|
|
11
|
El-Rayes BF, Ali S, Heilbrun LK, Lababidi
S, Bouwman D, Visscher D and Philip PA: Cytochrome P450 and
glutathione transferase expression in human breast cancer. Clin
Cancer Res. 9:1705–1709. 2003.PubMed/NCBI
|
|
12
|
Sandanaraj E, Lal S, Selvarajan V, Ooi LL,
Wong ZW, Wong NS, Ang PC, Lee EJ and Chowbay B: PXR
pharmacogenetics: association of haplotypes with hepatic CYP3A4 and
ABCB1 messenger RNA expression and doxorubicin clearance in Asian
breast cancer patients. Clin Cancer Res. 14:7116–7126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dixon RA and Steele CL: Flavonoids and
isoflavonoids - a gold mine for metabolic engineering. Trends Plant
Sci. 4:394–400. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Francis AR, Shetty TK and Bhattacharya RK:
Modulating effect of plant flavonoids on the mutagenicity of
N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis. 10:1953–1955.
1989.PubMed/NCBI
|
|
15
|
Hanasaki Y, Ogawa S and Fukui S: The
correlation between active oxygens scavenging and antioxidative
effects of flavonoids. Free Radic Biol Med. 16:845–850. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang SH, Hou YC, Chang WC, Hsiu SL, Chao
P-DL and Chiang BL: Morin sulfates/glucuronides exert
anti-inflammatory activity on activated macrophages and decreased
the incidence of septic shock. Life Sci. 74:743–756. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hodek P, Trefil P and Stiborova M:
Flavonoids - potent and versatile biologically active compounds
interacting with cytochromes P450. Chem Biol Interact. 139:1–21.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S and Morris ME: Effects of the
flavonoids biochanin A, morin, phloretin, and silymarin on
P-glycoprotein-mediated transport. J Pharmacol Exp Ther.
304:1258–1267. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Yun JK and Choi JS: Effects of morin
on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos.
28:151–156. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shin SC, Piao YJ and Choi JS: Effects of
morin on the bioavailability of tamoxifen and its main metabolite,
4-hydroxytamoxifen, in rats. In Vivo. 22:391–396. 2008.PubMed/NCBI
|
|
21
|
Piao YJ and Choi JS: Effects of morin on
the pharmacokinetics of nicardipine after oral and intravenous
administration of nicardipine in rats. J Pharm Pharmacol.
60:625–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong SS, Jin MJ and Han HK: Enhanced
systemic availability of methotrexate in the presence of morin in
rats. Biopharm Drug Dispos. 29:189–193. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pathak SM and Udupa N: Pre-clinical
evidence of enhanced oral bioavailability of the P-glycoprotein
substrate talinolol in combination with morin. Biopharm Drug
Dispos. 31:202–214. 2010.PubMed/NCBI
|
|
24
|
Russo J and Russo IH: Atlas and histologic
classification of tumors of rat mammary gland. J Mammary Gland Biol
Neoplasia. 5:187–200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim YC, Lee I, Kim SG, Ko SH, Lee MG and
Kim SH: Effects of glucose supplementation on the pharmacokinetics
of intravenous chlorzoxazone in rats with water deprivation for 72
hours. Life Sci. 79:2179–2186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang SH, Lee JH, Lee DY, Lee MG, Lyuk KC
and Kim SH: Effects of morin on the pharmacokinetics of docetaxel
in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary
tumors. Arch Pharm Res. 34:1729–1734. 2011.PubMed/NCBI
|
|
27
|
Fendl KC and Zimniski SJ: Role of
tamoxifen in the induction of hormone-independent rat mammary
tumors. Cancer Res. 52:235–237. 1992.PubMed/NCBI
|
|
28
|
Huggins C, Grand LC and Brillantes FP:
Mammary cancer induced by a single feeding of polymucular
hydrocarbons, and its suppression. Nature. 189:204–207. 1961.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee DY, Jung YS, Kim YC, Kim SY and Lee
MG: Faster clearance of omeprazole in mutant Nagase analbuminemic
rats: possible roles of increased protein expression of hepatic
CYP1A2 and lower plasma protein binding. Biopharm Drug Dispos.
30:107–116. 2009. View Article : Google Scholar
|
|
30
|
Øie S and Guentert TW: Comparison of
equilibrium times in dialysis experiments using spiked plasma or
spiked buffer. J Pharm Sci. 71:127–128. 1982.PubMed/NCBI
|
|
31
|
Choi YH, Lee I and Lee MG: Effects of
cysteine on metformin pharmacokinetics in rats with protein-calorie
malnutrition: partial restoration of some parameters to control
levels. J Pharm Pharmacol. 60:153–161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shirazi FH, Bahrami G, Stewart DJ, Tomiak
E, Delorme F, Noel D and Goel R: A rapid reversed phase high
performance liquid chromatographic method for determination of
etoposide (VP-16) in human plasma. J Pharm Biomed Anal. 25:353–356.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SH, Choi YM and Lee MG:
Pharmacokinetics and pharmacodynamics of furosemide in
protein-calorie malnutrition. J Pharmacokinet Biopharm. 21:1–17.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Piao YJ, Li X and Choi JS: Effects of
verapamil on etoposide pharmacokinetics after intravenous and oral
administration in rats. Eur J Drug Metab Pharmacokinet. 33:159–164.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X and Choi JS: Effects of quercetin on
the pharmacokinetics of etoposide after oral or intravenous
administration of etoposide in rats. Anticancer Res. 29:1411–1415.
2009.PubMed/NCBI
|
|
36
|
Suh JH, Kang HE, Yoon IS, Yang SH, Lee HJ,
Shim CK and Lee MG: Cysteine effects of cysteine on the
pharmacokinetics of etoposide in protein-calorie malnutrition rats:
increased gastrointestinal absorption by cysteine. Xenobiotica.
41:885–894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gibaldi M and Perrier D: Pharmacokinetics.
2nd edition. Marcel-Dekker; New York: 1982
|
|
38
|
Chiou WL: Critical evaluation of the
potential error in pharmacokinetic studies using the linear
trapezoidal rule method for the calculation of the area under the
plasma level-time curve. J Pharmacokinet Biopharm. 6:539–546. 1978.
View Article : Google Scholar
|
|
39
|
Mitruka BM and Rawnsley HM: Clinical
Biomedical and Hematological Reference Values in Normal
Experimental Animals and Normal Humans. 2nd edition. Masson
Publishing USA Inc; New York: pp. 161–162. 1981
|
|
40
|
Hande K, Anthony L, Hamilton R, Bennett R,
Sweetman B and Branch R: Identification of etoposide glucuronide as
a major metabolite of etoposide in the rat and rabbit. Cancer Res.
48:1829–1834. 1988.PubMed/NCBI
|
|
41
|
Hande K, Bennett R, Hamilton R, Grote T
and Branch R: Metabolism and excretion of etoposide in isolated,
perfused rat liver models. Cancer Res. 48:5692–5695.
1988.PubMed/NCBI
|
|
42
|
Wilkinson GR and Shand DG: A physiological
approach to hepatic drug clearance. Clin Pharmacol Ther.
18:377–390. 1975.PubMed/NCBI
|
|
43
|
Kan WM, Liu YT, Hsiao CL, Shieh CY, Kuo
JH, Huang JD and Su SF: Effect of hydroxyzine on the transport of
etoposide in rat small intestine. Anticancer Drugs. 12:267–273.
2001. View Article : Google Scholar : PubMed/NCBI
|
